References
- Nankervis H, Thomas KS, Delamere FM i wsp. Scoping systematic review of treatments for eczema. Programme Grants Appl Res. 2016;4(7):1-528.
- Pytkowska K, Głowacka K, Arct J. Lanolina i surowce z niej otrzymywane we współczesnej kosmetologii. Świat Przemysłu Kosmetycznego. 2014;3(19):49-53.
- Loden M. The increase in skin hydration after application of emollients with different amounts of lipids. Acta Derm Venereol. 1992;72:327-330.
- van Zuuren EJ, Fedorowicz Z, Christensen R i wsp. Emollients and moisturisers for eczema. Cochrane Database Syst Rev. 2017;2:1-423. CD02119.
- Farage MA, Hood W, Odio M i wsp. Skin Surface pH and topical emollient: fact or artifact? JJ Expt Derm Res. 2015;1(4):019-026.
- Hon KL, Kung JSC, Ng WGG, Leung TF. Emollient treatment of atopic dermatitis: latest evidence and clinical considerations. Drugs in Context. 2018;7:212530. Doi: 10.7573/dic.212530.
- Czarnecka-Operacz M, Sadowska-Przytocka A. Pielęgnacja skóry chorego na AZS w świetle nowoczesnej wiedzy medycznej. Alergia. 2015;3:24-28.
- Rissman R, Oudshoorn MH, Kocks i wsp. Lanolin-derived lipid mixtures mimic closely the lipid composition and organization of vernix caseosa lipids. Biochim Biophys Acta. 2008;1778(10):2350-2360.
- Czarnowicki T, Malajian D, Khattri S i wsp. Petrolatum: Barrier repair and antimicrobial responses underlying this „inert” moisturizer. J Allergy Clin Immunol. 2016;137:1091-1102.
- Scientific Opinion on the use of high viscosity white mineral oils as a food additive. EFSA Panel on Food Additives and Nutrient Sources added to Food (ANS). EFSA Journal 2009;7(11):1387,1-39.
- Garty BZ. High plasma urea concentration in babies with lamellar ichtyosis. Arch Dis Child. 1986;61:696-698.
- Werfel T, Heratizadeh A, Aberer W i wsp. S2k guideline on diagnosis and treatment of atopic dermatitis – short version. Allergo J Int. 2016;25:82-95.
- Kerschner M, Williams S. Skin care in atopic eczema. [w]: Ring J., Przybilla B., Ruzicka T. (red): Handbook of Atopic Eczema. Springer Berlin, Heidelberg, 2006; 524-533.
- Wollenberg A, Oranje A, Deleuran M i wsp. ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients. JEADV 2016;30:729-747.
- Manuschiatti W, Maibach HI. Hyaluronic acid and skin: wound healing and aging. Int J Dermatol. 1996;35(8):539-544.
- Cosmetic Ingredient Review Expert Panel Report. Safety assessment of panthenol, panthotenic acid, and derivatives as used in cosmetics. CIR. 2017, Washington, 1-52.
- Hoare C, Li Wan Po A, Williams H. Systematic review of treatments for atopic eczema. Health Technol Assess 2000;4 (37):1-8.
- Palmer CN, Irvine AD, Terron-Kwiatkowski A i wsp. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet. 2006;38:441-446.
- Elias PM. Lipid abnormalities and lipid-based repair strategies in atopic dermatitis. Biochim Biophys Acta. 2014;1841(3):323-330.
- Kezic S, Kemperman PM, Koster ES i wsp. Loss-of-function mutations in the filaggrin gene lead to reduced level of natural moisturizing factor in the stratum corneum. J Invest Dermatol 2008;128:2117-2119.
- Kim BE, Leung DYM. Significance of skin barrier dysfunction in atopic dermatitis. Allergy Asthma Immunol Res. 2018;10(3):207-215.
- Kennedy EA, Connolly J, Hourihane JO`B i wsp. Skin microbiome before development of atopic dermatitis: early colonization with commensal staphylococci at 2 months is associated with a lower risk of atopic dermatitis at 1 year. J Allergy Clin Immunol. 2017;139:166-172.
- Petry V, Lipnharski C, Bessa GR, Silveira VB, Weber MB. Prevalence of community-acquired methicillin-resistant Staphylococcus aureus and antibiotic resistance in patients with atopic dermatitis in Porto Alegre, Brazil. Intern J Dermatol. 2013;53(6):731-735.
- Meylan P, Lang C, Mermoud S i wsp. Skin colonization by Staphylococcus aureus precedes the clinical diagnosis of atopic dermatitis in infancy. J Invest Dermatol. 2017;137(12):2497-2504.
- Berardesca E, Barbareschi M, Veraldi S, Pimpinelli N. Evaluation of efficacy of a skin lipid mixture in patients with irritant contact dermatitis, allergic contact dermatitis or atopic dermatitis: a multicenter study. Contact Dermatitis 2001;45:280–285. http://dx.doi.org/10.1034/j.1600-05362001.450505.x.
- Loden M, Andersson AC, Andersson C i wsp. Instrumental and dermatologist evaluation of the effect of glycerine and urea on dry skin in atopic dermatitis. Skin Res Technol 2001;7:209-213. doi.org/10.1034/j.1600-0846.2001.070401.x.
- Loden M, Andersson AC, Anderson C i wsp. A double-blind study comparing the effect of glycerin and urea on dry, eczematous skin in atopic patients. Acta Derm Venereol 2002;82:45-47. doi.org/10.1080/000155502753600885.
- Amichai B, Grunwald MH. A randomized, double-blind, placebo-controlled study to evaluate the efficacy in AD of liquid soap containing 12% ammonium lactate + 20% urea. Clin Exp Dermatol 2009;34:e602-604. doi.org/10.1111/j.1365-2230.2009.03273.x.
- Sugarman JL, Parish LC. Efficacy of a lipid-based barrier repair formulation in moderate-to- severe pediatric atopic dermatitis. J Drugs Dermatol 2009;8:1106-1111.
- Bissonette R, Maari C, Provost N i wsp. A double-blind study of tolerance and efficacy of a new urea-containing moisturizer in patients with atopic dermatitis. J Cosmet Dermatol 2010; 9:16-21. 10.1111/j.1473-2165.2010.00476.x.
- Draelos ZD. A clinical evaluation of the comparable efficacy of hyaluronic acid-based foam and ceramide-containing emulsion cream in the treatment of mild-to-moderate atopic dermatitis. J Cosmet Dermatol. 2011;10:185-188. doi.org/10.1111/j.1473-2165.2011.00568.x.
- Wiren K, Nohlgard C, Nyberg F i wsp. Treatment with a barrier-strengthening moisturizing cream delays relapse of atopic dermatitis: a prospective and randomized controlled clinical trial. JEADV 2009;23:1267-1272.
- Lucky AW, Leach AD, Laskarzewski P i wsp. Use of an emollient as a steroid-sparing agent in the treatment of mild to moderate atopic dermatitis in children. Pediatr Dermatol. 1997;14:321-324.
- Loden M, Andersson AC, Lindberg M. Improvement in skin barrier function in patients with atopic dermatitis after treatment with a moisturizing cream (Canoderm). Br J Dermatol 1999; 140: 264-267.
- Grimalt R, Mengeaud V, Cambazard F, Study Investigators Group. The steroid-sparing effect of an emollient therapy in infants with atopic dermatitis: a randomized controlled study. Dermatology 2007; 214: 61-67. doi.org/10.1159/000096915
- Msika P, De Belilovsky C, Piccardi N i wsp. New emollient with topical corticosteroid-sparing effect in treatment of childhood atopic dermatitis: SCORAD and quality of life improvement. Pediatr Dermatol. 2008;25:606-612. doi.org/10.1111/j.1525-1470.2008.00783.x.
- De Belilovsky C, Roo-Rodriguez E, Baudouin C i wsp. Natural peroxisome proliferator-activated receptor-alpha agonist cream demonstrates similar therapeutic response to topical steroids in atopic dermatitis. J Dermatolog Treat. 2011;22:359-365. doi.org/10.3109/09546634.2010.499932.
- Simpson E, Dutronc Y. A new body moisturizer increases skin hydration and improves atopic dermatitis symptoms among children and adults. J Drugs Dermatol. 2011;10:744-749.
- Glatz M, Jo JH, Kennedy EA i wsp. Emollient use alters skin barrier and microbes in infants at risk for developing atopic dermatitis. Plos One. 2018;13(2):e0192443.
- Simpson EL, Chalmers JR, Hanifin JM i wsp. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. J Allergy Clin Immunol. 2014;134:818-823.
- Horimukai K, Morita K, Narita M i wsp. Application of moisturizer to neonates prevents development of atopic dermatitis. J Allergy Clin Immunol. 2014;134:824-830.e6.
- Darmstadt GL, Ahmed S, Ahmed AS, Saha SK. Mechanism for prevention of infection in preterm neonates by topical emollients: a randomized, controlled clinical trial. Pediatr Infect Dis J. 2014;33(11):1124-1127.
- Belloni G, Pinelli S, Veraldi S. A randomized, double-blind, vehicle-controlled study to evaluate the efficacy and safety of MAS063DP (Atopiclar) in the treatment of mild to moderate atopic dermatitis. Eur J Dermatol 2005;15:31-36.
- Abramovits W, Boguniewicz M for the Adult Atopiclar Study Group. A multicenter, randomized, vehicle-controlled clinical study to examine the efficacy and safety of MAS063DP (Atopiclar) in the management of mild to moderate atopic dermatitis in adults. J Drugs Dermatol. 2006;5:236-244.
- Boguniewicz M, Zeichner JA, Eichenfield LF i wsp. MAS063DP is effective monotherapy for mild to moderate atopic dermatitis in infants and children: a multicenter, randomized, vehicle-controlled study. J Pediatr 2008;152:854-859.
- Patrizi A, Capitanio B, Neri I i wsp. A double-blind, randomized, vehicle-controlled clinical study to evaluate the efficacy and safety of MAS063DP (Atopiclar) in the management of atopic dermatitis in paediatric patients. Pediatr Allergy Immunol. 2008;19:619-625.
- Miller DW, Koch SB, Yentzer BA i wsp. An over-the-counter moisturizer is a clinically effective as, and more cost-effective than, prescription barrier creams in the treatment of children with mild-to-moderate atopic dermatitis: a randomized, controlled trial. J Drugs Dermatol. 2011;10:531-537.
- Eichenfield LE, Ahluwalia J, Waldman A i wsp. Current guidelines for the evaluation and management of atopic dermatitis: A comparison of the Joint Task Force Practice Parameter and American Academy of Dermatology Guidelines. J Allergy Clin Immunol. 2017;139(4S):S49-S57. 10.1016/j.jaci.2017.01.009.
- Scottish Intercollegiate Guidelines Network (SIGN. Management of atopic eczema in primary care. SIGN publication no. 125. Edinburgh, SIGN, 2011.